Alteration of Serotonin 2C Receptor Expression in the Aorta and the Pulmonary Artery in Rats Exposed to Hypoxia

Bo Zhang；Yi Liu；Ying Luo；Wen Niu；Zhi-Chao Li

aorta ； hypoxia ； pulmonary artery ； receptor ； serotonin

The Chinese Journal of Physiology

51卷6期（2008 / 12 / 01）

338 - 347

英文

In the present study we reported the expression of the 5-HT(subscript 2C) receptor (5-HT(subscript 2C)-R) in the aorta and the pulmonary artery in rats exposed to hypoxia, and examined its role in vascular smooth muscle cells. Immunochemistry, quantitative RT-PCR, and western blot were used to examine 5-HT(subscript 2C)-R expression. Small interfering RNA (siRNA) was used to explore the role of 5-HT(subscript 2C)-R in vascular smooth muscle cells proliferation and contraction induced by 5-HT.5-HT(subscript 2C)-R immunoreactivity was confined predominantly to the plasma membrane in the rat aortic smooth muscle cells (ASMCs) and the pulmonary arterial smooth muscle cells (PASMCs). 5-HT(subscript 2C)-R mRNA expression in the aorta of hypoxic pulmonary hypertension (HPH) rats was more than that in the pulmonary artery. Hypoxia-induced 5-HT(subscript 2C)-R protein expression in the aorta was less than that in the pulmonary artery, indicating that 5-HT(subscript 2C)-R might mediate different responses of the aorta and the pulmonary artery to 5-HT in HPH. We also demonstrated that RNA editing may not be involved in the different expression levels of 5-HT(subscript 2C)-R in the aorta and the pulmonary artery. The higher expression of 5-HT(subscript 2C)-R in the pulmonary artery versus the aorta of HPH rats was partly due to the increased protein stability. siRNA was used to knock down the expression of 5-HT(subscript 2C)-R. 5-HT(subscript 2C)-R-specific siRNA reduced the proliferation and contraction of vascular smooth muscle cells induced by 5-HT. In conclusion, the different expression patterns of 5-HT(subscript 2C)-R protein in the aorta and the pulmonary artery suggest that this 5-HT receptor may be involved, at least partly, in modulating different responses of systemic vessels and pulmonary vasculature to 5-HT in HPH.

1. Bialecki, R.A.,Fisher, C.S.,Murdoch, W.W.,Barthlow, H.G.,Stow, R.B.,Mallamaci, M.,Rumsey, W.(1998).Hypoxic exposure time dependently modulates endothelin-induced contraction of pulmonary artery smooth muscle.Am. J. Physiol.,274,552-559.
2. Bubar, M.J.,Seitz, P.K.,Thomas, M.L.,Cunningham, K.A.(2005).Validation of a selective serotonin 5-HT2C receptor antibody for utilization in fluorescence immunohistochemistry studies.Brain. Res.,1063,105-113.
3. Burns, C.M.,Chu, H.,Rueter, S.M.,Hutchinson, L.K.,Canton, H.,Sanders-Bush, E.,Emeson, R.B.(1997).Regulation of serotonin-2C receptor G-protein coupling by RNA editing.Nature,387,303-308.
4. Calama, E.,Moran, A.,Ortiz de Urbina, A.V.,Martin, M.L.,San Roman, L.(2004).Vasoconstrictor responses to 5-hydroxytryptamine in the autoperfused hindquarters of spontaneously hypertensive rats.Pharmacology,71,66-72.
5. Canton, H.,Emeson, R.B.,Barker, E.L.,Backstrom, J.R.,Lu, J.T.,Chang, M.S.,Sanders-Bush, E.(1996).Identification, molecular cloning and distribution of a short variant of the 5-hydroxytryptamine2C receptor produced by alternative splicing.Mol. Pharmacol.,50,799-807.
6. Chamley-Campbell, J.,Camplell, G.R.,Ross, R.(1979).The smooth muscle cell in culture.Physiol. Rev.,59,1-61.
7. Dumas, J.P.,Bardou, M.,Goirand, F.,Dumas, M.(1999).Hypoxic pulmonary vasoconstriction.Gen. Pharmacol.,33,289-297.
8. Fernandez, M.M.,Moran, A.,Martin, M.L.,San Roman, L.(2000).Mesenteric vasoconstrictor response to 5-hydroxytryptamine in the in situ blood autoperfused rat mesentery: involvement of 5-HT2B and/or 5-HT2C receptor activation.Eur. J. Pharmacol.,401,221-227.
9. Humphrey, P.P.,Hartig, P.,Hoyer, D.(1993).A proposed new nomenclature for 5-HT receptors.Trends. Pharmacol. Sci.,14,233-236.
10. Iwamoto, K.,Nakatani, N.,Bundo, M.,Yoshikawa, T.,Kato, T.(2005).Altered RNA editing of serotonin 2C receptor in a rat model of depression.Neurosci. Res.,53,69-76.
11. Jeffery, T.K.,Morrell, N.W.(2002).Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension.Prog. Cardiovasc. Dis.,45,173-202.
12. Julius, D.,Livelli, T.J.,Jessell, T.M.,Axel, R.(1989).Ectopic expression of the serotonin lc receptor and the triggering of malignant transformation.Science,244,1057-1062.
13. Keegan, A.,Morecroft, I.,Smillie, D.,Hicks, M.N.,MacLean, M.R.(2001).Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/1D-receptor antagonist GR127935.Circ. Res.,89,1231-1239.
14. Keegan, L.P.,Gallo, A.,O`Connell, M.A.(2001).The many roles of an RNA editor.Nat. Rev. Genet.,2,869-878.
15. Kereveur, A.,Callebert, J.,Humbert, M.,Herve, P.,Simonneau, G.,Launay, J.M.(2000).High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (Prostacyclin) therapy.Arterioscler. Thromb. Vasc. Biol.,20,2233-2239.
16. Lai, Y.L.,Chen, C.F.,Chien, C.T.,Shiao, H.L.,Thacker, A.A.,Zhang, H.Q.(1995).Capsaicin pretreatment attenuates chronic hypoxic pulmonary hypertension.Respir. Physiol.,99,283-289.
17. Launay, J.M.,Herve, P.,Peoc`h, K.,Tournois, C.,Callebert, J.,Nebigil, C.G.,Etienne, N.,Drouet, L.,Humbert, M.,Simonneau, G.,Maroteaux, L.(2002).Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.Nat. Med.,8,1129-1135.
18. Li, Z.C.,Zhang, F.Q.,Song, J.C.,Mei, Q.B.,Zhao, D.H.(2002).Therapeutic effects of DCDDP, a calcium channel blocker, on chronic pulmonary hypertension in rat.J. Appl. Physiol.,92,997-1003.
19. Liao, X.,Tang, S.,Thrasher, J.B.,Griebling, T.L.,Li, B.(2005).Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer.Mol. Cancer. Ther.,4,505-515.
20. Livak, K.J.,Schmittgen, T.D.(2001).Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method.Methods,25,402-408.
21. Maclean, M.R.,Herve, P.,Eddahibi, S.,Adnot, S.(2000).5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.Brit. J. Pharmacol.,131,161-168.
22. MacLean, M.R.,Sweeney, G.,Baird, M.,McCulloch, K.M.,Houslay, M.,Morecroft, I.(1996).5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats.Brit. J. Pharmacol.,119,917-930.
23. Marcos, E.,Fadel, E.,Sanchez, O.,Humbert, M.,Dartevelle, P.,Simonneau, G.,Hamon, M.,Adnot, S.,Eddahibi, S.(2004).Serotonininduced smooth muscle hyperplasia in various forms of human pulmonary hypertension.Circ. Res.,94,1263-1270.
24. Ogretmen, B.,Safa, A.R.(1997).Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistan MCF-7/Adr human breast cancer cells.Oncogene,14,499-506.
25. Pitt, B.R.,Weng, W.,Steve, A.R.,Blakely, R.D.,Reynolds, I.,Davies, P.(1994).Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture.Am. J. Physiol.,266,178-186.
26. Reenan, R.A.(2001).The RNA world meets behavior: A-I pre-mRNA editing in animals.Trends Genet.,17,53-56.
27. Sharma, S.K.,Zahradka, P.,Chapman, D.,Kumamoto, H.,Takeda, N.,Dhalla, N.S.(1999).Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate.J. Pharmacol. Exp. Ther.,290,1475-1481.
28. Smith, B.M.,Thomsen, W.J.,Grottick, A.J.(2006).The potential use of selective 5-HT2C adonists in treating obesity.Expert. Opin. Investig. Drugs.,15,257-266.
29. Sukma, M.,Tohda, M.,Watanabe, H.,Matsumoto, K.(2005).The mRNA expression differences of RNA editing enzymes in differentiated and undifferentiated NG108-15 cells.J. Pharmacol. Sci.,98,467-470.
30. Thomas, B.J.,Wanstall, J.C.(2003).Alterations in pulmonary vascular function in rats exposed to intermittent hypoxia.Eur. J. Pharmacol.,477,153-161.
31. Tohda, M.,Nomura, M.,Nomura, Y.(2006).Molecular pathopharmacology of 5-HT2C receptors and the RNA editing in the brain.J. Pharmacol. Sci.,100,427-432.
32. Ullmer, C.,Schmuck, K.,Kalkman, H.O.,Lubbert, H.(1995).Expression of serotonin receptor mRNAs in blood vessels.FEBS Lett.,370,215-221.
33. Von Euler, U.S.,Liljestrand, G.(1946).Observations on the pulmonary arterial blood pressure in the cat.Acta. Physiol. Scand.,12,301-320.
34. Wang, D.,Post, M.,Cutz, E.(1999).Expression of serotonin receptor 2C in rat type II pneumocytes.Am. J. Resp. Cell. Mol.,20,1175-1180.
35. Wang, Q.,O`Brien, P.J.,Chen, C.X.,Cho, D.S.,Murray, J.M.,Nishikura, K.(2000).Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin-2c receptors.J. Neurochem.,74,1290-1300.
36. Wanstall, J.C.,O`Donnell, S.R.(1992).Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats.Brit. J. Pharmacol.,105,152-158.
37. Wanstall, J.C.,O`Donnell, S.R.(1990).Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension.Eur. J. Pharmacol.,176,159-168.
38. Welsh, D.J.,Scott, P.,Plevin, R.,Wadsworth, R.,Peacock, A.J.(1998).Hypoxia enhances cellular proliferation and inositol 1,4,5-triphosphate generation in fibroblasts from bovine the pulmonary artery but not from mesenteric artery.Am. J. Resp. Crit. Care.,158,1757-1762.
39. Xie, E.,Zhu, L.,Zhao, L.,Chang, L.S.(1996).The human serotonin 5-HT2C receptor: complete cDNA, genomic structure and alternatively spliced variant.Genomics,35,551-561.
40. Zamore, P.D.(2001).RNA interference: listening to the sound of silence.Nat. Struct. Biol.,8,746-750.

1. Zhang, Bo,Niu, Wen,Luo, Ying,Liu, Yi,Li, Zhi-Chao,Gao, Yu-Qi,Dong, Ming-Qing(2010).Attenuation of Pulmonary Arterial Smooth Muscle Cell Proliferation Following Hypoxic Pulmonary Hypertension by the Na+/H+ Exchange Inhibitor Amiloride.Chinese Journal of Physiology,53(1),36-44.